Stay updated with breaking news from Marinu Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC ...
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its...
ZTALMY® can now be prescribed by healthcare professionals in the U.S.Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical developmentMarinus’ Phase 2 refractory status epilepticus (RSE) trial data published in Epilepsia in June...